Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

GPR3 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the GPR52 Receptor in transfected HEK293 cells
GPR52 (non-phospho), G protein-coupled...
The non-phospho-GPR52 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR52. It can be used to detect total GPR52 receptors in Western blots independent of phosphorylation. The GPR52 antibody...
CHF400.00 *
Details

GPR52 (G Protein-Coupled Receptor 52) is an orphan GPCR that has gained attention due to its potential involvement in neuropsychiatric and neurological disorders. It has been suggested to have roles in dopamine signaling, though its precise endogenous ligand remains unidentified. GPR52 is primarily expressed in the brain, particularly in areas involved in dopaminergic signaling, such as the striatum and prefrontal cortex. It is also found in certain regions involved in mood regulation, motor control, and cognitive functions. GPR52 is considered a potential pharmacological target for the treatment of neuropsychiatric disorders, such as Parkinson's disease, schizophrenia, and other dopamine-related conditions. Its involvement in dopaminergic pathways suggests it could be targeted to modulate dopamine activity, potentially improving symptoms of movement disorders or psychiatric conditions. Although research into GPR52 is still in early stages, the receptor is being explored for the development of selective modulators that could offer new treatment options for neurodegenerative diseases and psychiatric disorders. For more information on GPR52 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR52 (G Protein-Coupled Receptor 52) is an orphan GPCR that has gained attention due to its potential involvement in neuropsychiatric and neurological disorders. It has been suggested to have... read more »
Close window
GPR3 Receptor Antibodies

GPR52 (G Protein-Coupled Receptor 52) is an orphan GPCR that has gained attention due to its potential involvement in neuropsychiatric and neurological disorders. It has been suggested to have roles in dopamine signaling, though its precise endogenous ligand remains unidentified. GPR52 is primarily expressed in the brain, particularly in areas involved in dopaminergic signaling, such as the striatum and prefrontal cortex. It is also found in certain regions involved in mood regulation, motor control, and cognitive functions. GPR52 is considered a potential pharmacological target for the treatment of neuropsychiatric disorders, such as Parkinson's disease, schizophrenia, and other dopamine-related conditions. Its involvement in dopaminergic pathways suggests it could be targeted to modulate dopamine activity, potentially improving symptoms of movement disorders or psychiatric conditions. Although research into GPR52 is still in early stages, the receptor is being explored for the development of selective modulators that could offer new treatment options for neurodegenerative diseases and psychiatric disorders. For more information on GPR52 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed